Evidence map›Paper›PMID 26517877›Full record

Trial reportPLoS neglected tropical diseases2015

Pilot Field Trial of the EG95 Vaccine Against Ovine Cystic Echinococcosis in Rio Negro, Argentina: Second Study of Impact.

Edmundo Larrieu, Guillermo Mujica, Charles G Gauci, Katherina Vizcaychipi, Marcos Seleiman, Eduardo Herrero, José Luis Labanchi, Daniel Araya, Luis Sepúlveda, Claudia Grizmado and 11 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Breaking the Cycle of Echinococcosis: A Mathematical Modeling Approach.Tropical medicine and infectious disease · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Cystic Echinococcosis in the Early 2020s: A Review.Tropical medicine and infectious disease · 2024
    Review
  7. Article
  8. Modelling diagnostics forOne health (Amsterdam, Netherlands) · 2022
    Article
  9. Article
  10. The RecombinantFrontiers in immunology · 2022
    Article
  11. Review
  12. Echinococcosis: Advances in the 21st Century.Clinical microbiology reviews · 2019
    Review
  13. Article
  14. Article
  15. Immunization of sheep againstVeterinary world · 2017
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Edmundo LarrieuFacultad de Ciencias Veterinarias, Universidad Nacional de La Pampa, General Pico, Argentina; Escuela de Veterinaria, Universidad Nacional de Río Negro, Choele Choel, Argentina.
Guillermo MujicaMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Charles G GauciFaculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, Australia.
Katherina VizcaychipiDepartamento de Parasitología "INEI- ANLIS", Buenos Aires, Argentina.
Marcos SeleimanMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Eduardo HerreroMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
José Luis LabanchiMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Daniel ArayaMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Luis SepúlvedaMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Claudia GrizmadoMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Arnoldo CalabroMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Gabriel TalmonMinisterio de Salud, Provincia de Río Negro, Viedma, Argentina.
Thelma Verónica PoggioCentro de Virología Animal (CEVAN), Instituto de Ciencia y Tecnología / Cesar Milstein-CONICET, Buenos Aires, Argentina.
Pablo CrowleyEscuela de Veterinaria, Universidad Nacional de Río Negro, Choele Choel, Argentina.
Graciela CespedesDepartamento de Parasitología "INEI- ANLIS", Buenos Aires, Argentina.
Graciela SantillánDepartamento de Parasitología "INEI- ANLIS", Buenos Aires, Argentina.
Mariela García CachauFacultad de Ciencias Veterinarias, Universidad Nacional de La Pampa, General Pico, Argentina.
Roberto LambertiFacultad de Ciencias Veterinarias, Universidad Nacional de La Pampa, General Pico, Argentina.
Lilia GinoFacultad de Ciencias Veterinarias, Universidad Nacional de La Pampa, General Pico, Argentina.
Meritxell DonadeuFaculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, Australia.
Marshall W LightowlersFaculty of Veterinary and Agricultural Sciences, University of Melbourne, Werribee, Australia.
Ministerio de Salud · ARUniversidad Nacional de La Pampa · ARUniversity of Melbourne · AUAdministración Nacional de Laboratorios e Institutos de Salud · ARNational University of Río Negro · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARInstitute of Parasitology · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCystic echinococcosis (CE) is an important zoonotic disease caused by the cestode parasite Echinococcus granulosus. It occurs in many parts of the world where pastoral activities predominate, including the Rio Negro province of Argentina. Although CE control activities have been undertaken in the western regions of Rio Negro for more than two decades, the disease continues to remain prevalent in both the human and livestock animal populations. Vaccination of animal intermediate hosts of CE with the EG95 vaccine may provide a new opportunity to improve the effectiveness of CE control measures, although data are lacking about field application of the vaccine.

aimsEvaluate the impact of EG95 vaccination in sheep on the transmission of Echinococcus granulosus in a field environment. METHODOLOGY: Two trial sites were established in western Rio Negro province within indigenous communities. Vaccination of lambs born into one trial site was introduced and continued for 6 years. Prior to initiation of the trial, and at the end of the trial, the prevalence of CE in sheep was determined by necropsy. Weaned lambs received two injections of EG95 vaccine, approximately one month apart, and a single booster injection one year later. Vaccination was not implemented at the second trial site. A total of 2725 animals were vaccinated in the first year. Animals from this cohort as well as age-matched sheep from the control area were evaluated by necropsy. KEY

resultsIntroduction of the vaccine led to a statistically significant in the number and size of hydatid cysts in comparison to the situation prior to the introduction of the vaccine, or compared to CE prevalence in the control area where the vaccine was not applied. The prevalence of infection in the vaccinated area was also significantly reduced by 62% compared to the re-intervention level, being lower than the prevalence seen in the control area, although the difference from the control area after the intervention was not significant possibly due to limitations in the numbers of animals available for necropsy.

conclusionsVaccination of sheep with the EG95 vaccine provides a valuable new tool which improves the effectiveness of CE control activities. Vaccination was effective even in a difficult, remote environment where only approximately half the lambs born into the communities were fully vaccinated.

Indexed as

AnimalsAntigens, HelminthArgentinaDisease Transmission, InfectiousEchinococcosisEchinococcus granulosusHelminth ProteinsImmunization ScheduleParasite LoadPrevalenceSheepSheep DiseasesTreatment OutcomeVaccinesAntigens, HelminthEG95 protein, Echinococcus granulosusHelminth ProteinsVaccines

Identifiers

PMID26517877
PMCPMC4627725
OpenAlexW1824405391

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.